Nandani Creation Ltd Right Issue 2024
- Published Date: July 12, 2024
- Updated Date: June 17, 2025
- By Team Choice
Nandani Creation Limited is launching a Rights Issue worth Rs 15.98 crore, available for subscription from 12 July 2024 to 23 July 2024. Shareholders will be entitled to 100 Rights equity shares for every 224 fully paid-up equity shares they own as of the record date, 4 July 2024. Each share has a face value of Rs. 10, and the issue price is set at Rs. 30 per share.
Stay tuned with us for comprehensive details on Nandani Creation Limited's 2024 Rights Issue, including the issue size, entitlement, payment terms, and more.
Objectives of Nandani Creation Rights Issue
The proceeds from the issue are intended to be used by the Company for the following purposes:
- Augmenting the existing and incremental working capital requirements of the company.
- Investing in our subsidiary, Desi Fusion Private Limited (DFPL), to fund its working capital requirements.
- General corporate purposes.
Nandani Creation Limited Rights Issue Of Shares Detail Overview 2024
| Corporate Action | |
|---|---|
| Security Name | Nandani Creation Ltd |
| Issue Open/Close | July 12, 2024-July 23, 2024 |
| Record Date | July 4, 2024 |
| Issue Size (Amount) | ₹15.98 Crores |
| Issue Size (Shares) | ₹5,327,656 |
| Right Issue Price | ₹30 per share |
| Face Value | ₹10 Per Shares |
| CMP | ₹44 |
| Renunciation of Rights Entitlements | July 18, 2024 |
| Terms of Payment | The entire amount of the Issue Price of 30/- per Rights Equity Share shall be payable at the time of Application. |
| Entitlement | 100 Rights Equity Shares for every 224 fully paid-up Equity Shares held on Record Date |
Disclaimer: The Information compiled by CEBPL on a best efforts basis from information CEBPL received from third party vendors, believed to be reliable. The information may contain errors or omissions; and is subject to change without prior or additional notice. CEBPL provides corporate action information that may be of interest or relevance to CEBPL clients. This does not constitute a recommendation or advice by CEBPL, and CEBPL Clients may not rely upon it. CEBPL does not warrant that the information provided is accurate, timely, or complete. CEBPL Clients are urged to verify the information prior to using it in their investing and trading decisions, including, but not limited to, referral to independent financial news resources, company announcements, and regulatory filings or disclosures. "Investment in securities market are subject to market risks, read all the related documents carefully before investing". Registration granted by SEBI and certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of retums to investors. Name of Compliance Officer-Prashant Salian Email Id-Prashant.salian@choiceindia.com Contact no. 022-67079999-Ext-2310. Name of Grievance Officer-Deepika Singhvi-Email Id-ig@choiceindia.com, Contact no. 022-67079999-Ext-834. www.choiceindia.com
Recommended for you
Indian Stock Market Prediction For Next Week
FII DII Data - Live Data
10 Best SIP Plans For ₹1000 Per Month in 2025
Pharma Mutual Funds – Best Option to Invest in 2025?
Invest in best pharma mutual funds in India for 2020 with Investica. Explore our top recommended pharma mutual funds to start investing today.